{
  "id": "trelegy-ellipta",
  "recordTier": "source_traceable_archive",
  "editorial": {
    "reviewedAt": "2026-08-19",
    "status": "published_traceable_archive"
  },
  "names": {
    "brand": "Trelegy Ellipta",
    "generic": "糠酸氟替卡松/乌美溴铵/维兰特罗",
    "aliases": [
      "TRELEGY ELLIPTA",
      "fluticasone furoate umeclidinium and vilanterol",
      "fluticasone furoate/umeclidinium/vilanterol",
      "糠酸氟替卡松/乌美溴铵/维兰特罗",
      "氟替卡松呋喃酸酯/乌美溴铵/维兰特罗"
    ],
    "marketBrandNames": [],
    "mainlandChinaTradeNameCue": null
  },
  "identity": {
    "therapeuticArea": "呼吸系统",
    "sourceArchiveMarket": "美国当前 TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗公开标签（DailyMed SPL v14：2025-11-19 发布）",
    "dosageFormClass": "三成分干粉吸入器：100/62.5/25 或 200/62.5/25 mcg/次吸入（当前美国标签所列）",
    "dosageFormClassCode": "inhaled_device",
    "route": "经口吸入",
    "routeCode": "inhalation",
    "historicalApprovalEntry": "2017（当前美国标签所列 Initial U.S. Approval）",
    "archiveSponsorText": "GlaxoSmithKline LLC / DailyMed（NLM）当前公开标签档案"
  },
  "matchPolicy": {
    "contract": "reviewed_name_and_exclusion_cues_v1",
    "exactMatchNames": [],
    "excludedProductCues": [
      "VENTOLIN",
      "albuterol",
      "salbutamol",
      "rescue inhaler",
      "ANORO ELLIPTA",
      "INCRUSE ELLIPTA",
      "BREO ELLIPTA",
      "fluticasone furoate and vilanterol",
      "umeclidinium and vilanterol",
      "急救吸入",
      "TRELEGY HFA",
      "hfa",
      "metered-dose inhaler",
      "nebulizer",
      "handihaler",
      "diskus"
    ],
    "exclusionPrecedence": "before_name_candidate"
  },
  "productPresentations": [
    {
      "id": "us-trelegy-ellipta-100-62-5-25-30-inhalations-ndc-0173-0887-10",
      "marketCode": "US",
      "labelVersion": {
        "zh": "DailyMed SPL v14（2025-11-19 发布）",
        "en": "DailyMed SPL v14 published 2025-11-19"
      },
      "dosageForm": {
        "zh": "三成分干粉吸入器",
        "en": "three-ingredient dry-powder inhaler"
      },
      "route": {
        "zh": "经口吸入",
        "en": "oral inhalation"
      },
      "routeCodes": [
        "oral_inhalation"
      ],
      "productCode": "NDC 0173-0887-10",
      "pouchCode": null,
      "applicationNumber": null,
      "presentationRole": null,
      "primaryStrengthBasisCode": "per_inhalation",
      "primaryDisplay": {
        "zh": "100/62.5/25 mcg／标签每次吸入；1 个 ELLIPTA 吸入器（30 次标签吸入；60 个泡罩）",
        "en": "100/62.5/25 mcg per labelled inhalation; one ELLIPTA inhaler (30 labelled inhalations; 60 blisters)"
      },
      "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&name=trelegy-ellipta-spl-graphic-26.jpg",
      "visualStatus": "exact_public_label_package_image",
      "labeledQuantities": [
        {
          "ingredient": {
            "zh": "糠酸氟替卡松",
            "en": "fluticasone furoate"
          },
          "value": 100,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        },
        {
          "ingredient": {
            "zh": "乌美溴铵",
            "en": "umeclidinium"
          },
          "value": 62.5,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        },
        {
          "ingredient": {
            "zh": "维兰特罗",
            "en": "vilanterol"
          },
          "value": 25,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        }
      ],
      "concentration": null,
      "container": {
        "typeCode": "dry_powder_inhaler",
        "typeLabel": {
          "zh": "ELLIPTA 干粉吸入器",
          "en": "ELLIPTA dry-powder inhaler"
        },
        "fill": null,
        "countPerPackage": 1,
        "countUnit": {
          "zh": "吸入器/盒",
          "en": "inhaler per carton"
        },
        "unitsPerContainer": {
          "count": 30,
          "unit": {
            "zh": "次标签吸入",
            "en": "labelled inhalations"
          }
        }
      },
      "deliveryDevice": {
        "typeCode": "ellipta_dry_powder_inhaler",
        "name": {
          "zh": "ELLIPTA 吸入器",
          "en": "ELLIPTA inhaler"
        }
      },
      "compatibleReusableDevice": null,
      "listingStatus": null,
      "package": {
        "count": 1,
        "unit": {
          "zh": "吸入器/盒（30 次标签吸入；60 个泡罩）",
          "en": "inhaler per carton (30 labelled inhalations; 60 blisters)"
        }
      },
      "physicalClues": null,
      "comparisonNotice": null,
      "source": {
        "id": "src_2a8f04a161167cfd",
        "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
        "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "product_label",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      },
      "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion"
    },
    {
      "id": "us-trelegy-ellipta-200-62-5-25-30-inhalations-ndc-0173-0893-10",
      "marketCode": "US",
      "labelVersion": {
        "zh": "DailyMed SPL v14（2025-11-19 发布）",
        "en": "DailyMed SPL v14 published 2025-11-19"
      },
      "dosageForm": {
        "zh": "三成分干粉吸入器",
        "en": "three-ingredient dry-powder inhaler"
      },
      "route": {
        "zh": "经口吸入",
        "en": "oral inhalation"
      },
      "routeCodes": [
        "oral_inhalation"
      ],
      "productCode": "NDC 0173-0893-10",
      "pouchCode": null,
      "applicationNumber": null,
      "presentationRole": null,
      "primaryStrengthBasisCode": "per_inhalation",
      "primaryDisplay": {
        "zh": "200/62.5/25 mcg／标签每次吸入；1 个 ELLIPTA 吸入器（30 次标签吸入；60 个泡罩）",
        "en": "200/62.5/25 mcg per labelled inhalation; one ELLIPTA inhaler (30 labelled inhalations; 60 blisters)"
      },
      "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&name=trelegy-ellipta-spl-graphic-27.jpg",
      "visualStatus": "exact_public_label_package_image",
      "labeledQuantities": [
        {
          "ingredient": {
            "zh": "糠酸氟替卡松",
            "en": "fluticasone furoate"
          },
          "value": 200,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        },
        {
          "ingredient": {
            "zh": "乌美溴铵",
            "en": "umeclidinium"
          },
          "value": 62.5,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        },
        {
          "ingredient": {
            "zh": "维兰特罗",
            "en": "vilanterol"
          },
          "value": 25,
          "unit": "mcg",
          "basisCode": "per_inhalation",
          "basisLabel": {
            "zh": "标签每次吸入的成分标示；不是个人使用指令",
            "en": "labelled ingredient amount per inhalation; not an individual's use instruction"
          }
        }
      ],
      "concentration": null,
      "container": {
        "typeCode": "dry_powder_inhaler",
        "typeLabel": {
          "zh": "ELLIPTA 干粉吸入器",
          "en": "ELLIPTA dry-powder inhaler"
        },
        "fill": null,
        "countPerPackage": 1,
        "countUnit": {
          "zh": "吸入器/盒",
          "en": "inhaler per carton"
        },
        "unitsPerContainer": {
          "count": 30,
          "unit": {
            "zh": "次标签吸入",
            "en": "labelled inhalations"
          }
        }
      },
      "deliveryDevice": {
        "typeCode": "ellipta_dry_powder_inhaler",
        "name": {
          "zh": "ELLIPTA 吸入器",
          "en": "ELLIPTA inhaler"
        }
      },
      "compatibleReusableDevice": null,
      "listingStatus": null,
      "package": {
        "count": 1,
        "unit": {
          "zh": "吸入器/盒（30 次标签吸入；60 个泡罩）",
          "en": "inhaler per carton (30 labelled inhalations; 60 blisters)"
        }
      },
      "physicalClues": null,
      "comparisonNotice": null,
      "source": {
        "id": "src_2a8f04a161167cfd",
        "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
        "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "product_label",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      },
      "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion"
    }
  ],
  "comparisonPresentations": [],
  "appearanceReferences": [],
  "visualReference": {
    "presentationId": null,
    "status": "historical_public_label_image_not_product_authentication",
    "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&name=trelegy-ellipta-spl-graphic-26.jpg",
    "alt": "TRELEGY ELLIPTA 在美国 DailyMed 当前标签中的 100/62.5/25 mcg、NDC 0173-0887-10、30 次吸入纸盒面板",
    "archiveMarket": "美国",
    "labelVersion": "DailyMed SPL v14（2025-11-19 发布）",
    "presentation": "TRELEGY ELLIPTA 三成分干粉吸入器：100/62.5/25 mcg/次吸入；NDC 0173-0887-10；30 次吸入（60 个泡罩）纸盒面板。",
    "notice": "此图只对应美国当前标签中的 TRELEGY ELLIPTA 100/62.5/25 mcg、NDC 0173-0887-10、30 次吸入纸盒。它不代表 200/62.5/25 mcg、14 次机构包装、其他 ELLIPTA 产品、其他吸入器或其他市场；不用于鉴定真伪，也不生成个人吸入步骤、次数、补用、转换或联合方案。",
    "source": {
      "id": "src_2a8f04a161167cfd",
      "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "dated_public_record",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    }
  },
  "visualCoverageNote": null,
  "labelReading": {
    "coverage": "drug_specific_source_review",
    "title": {
      "zh": "TRELEGY ELLIPTA 说明书放大阅读：100/62.5/25 是三种成分和一个装置的身份",
      "en": "TRELEGY ELLIPTA label reading: 100/62.5/25 identifies three ingredients and one device"
    },
    "summary": {
      "zh": "本模块以当前美国公开标签为阅读入口，帮助核对 TRELEGY ELLIPTA、三种成分、完整三数字、干粉吸入装置、NDC 与标签版本。它不决定个人吸入次数、装置操作、是否与另一吸入药同用、如何加减或急性症状时应自行如何处理。",
      "en": "This module uses the current U.S. public label to check TRELEGY ELLIPTA, all three ingredients, the complete three-number marking, dry-powder inhaler, NDC and label version. It does not decide individual inhalation use, device operation, co-use with another inhaler, adjustment or self-management of an acute symptom."
    },
    "checks": [
      {
        "zh": "100/62.5/25 与 200/62.5/25 mcg 是每次吸入中三种成分的完整标示，不是可由网页拆成、相加或换成个人吸入次数的公式。还要同时核对装置、NDC、包装次数、目标市场和标签版本。",
        "en": "100/62.5/25 and 200/62.5/25 mcg are complete three-ingredient markings per inhalation, not a formula a webpage can split, add or convert into an individual's inhalation use. Also check the device, NDC, pack count, target market and label version together."
      },
      {
        "zh": "TRELEGY ELLIPTA 与 VENTOLIN HFA、ANORO ELLIPTA、INCRUSE ELLIPTA、BREO ELLIPTA 或其他吸入产品并不因都出现“吸入”“ELLIPTA”或一项共同成分而可自行叠加、轮换、替代或共用装置。",
        "en": "TRELEGY ELLIPTA is not self-combinable, alternatable, substitutable or device-shareable with VENTOLIN HFA, ANORO ELLIPTA, INCRUSE ELLIPTA, BREO ELLIPTA or another inhaler merely because labels mention inhalation, ELLIPTA or one shared ingredient."
      },
      {
        "zh": "当前标签明确其不用于缓解急性支气管痉挛。突发或加重的呼吸困难、胸痛、发绀、说话困难、昏厥或其他急性担忧，应依当地紧急医疗计划和医生指示处理，而不是根据本页自行加用、补用或改用吸入产品。",
        "en": "The current label states it is not indicated for relief of acute bronchospasm. Sudden or worsening breathing difficulty, chest pain, cyanosis, trouble speaking, fainting or another acute concern needs the local urgent-care plan and clinician guidance, not self-added, make-up or changed inhaler use from this page."
      },
      {
        "zh": "吸入装置的开封、储存、清洁、吸入动作和剩余剂量计数都应回到实际产品的患者说明和药师/开方团队演示；网页只帮助定位准确标签，不能替代装置教学。",
        "en": "Device opening, storage, cleaning, inhalation technique and remaining-dose counting must return to the patient instructions for the actual product and demonstration by a pharmacist/prescribing team; this page only helps locate the exact label and cannot replace device teaching."
      }
    ],
    "source": {
      "id": "src_2a8f04a161167cfd",
      "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "dated_public_record",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "scope": "label_literacy_only_no_individual_dosing_or_substitution"
  },
  "mechanismReading": {
    "title": {
      "zh": "三种吸入成分怎样协同出现：ICS、抗胆碱能与长效 β₂ 激动剂路径",
      "en": "How three inhaled ingredients appear together: ICS, anticholinergic and long-acting beta2-agonist pathways"
    },
    "summary": {
      "zh": "当前标签将 TRELEGY ELLIPTA 描述为吸入性糖皮质激素糠酸氟替卡松、抗胆碱能成分乌美溴铵和长效 β₂ 肾上腺素能激动剂维兰特罗的固定复方。机制帮助理解为什么完整药单与装置核对重要，不预测个人肺功能、急性症状、疗效、吸入次数或能否换药。",
      "en": "The current label describes TRELEGY ELLIPTA as a fixed combination of the inhaled corticosteroid fluticasone furoate, the anticholinergic umeclidinium and the long-acting beta2-adrenergic agonist vilanterol. Mechanism helps explain why complete-list and device review matters; it does not predict individual lung function, acute symptoms, benefit, inhalation use or whether a switch is suitable."
    },
    "checks": [
      {
        "zh": "三条作用路径不表示可以自行增加其他含 LABA、抗胆碱能药或吸入性糖皮质激素的产品。任何新增、停用、轮换或替代都需要让药师或医生逐项核对完整药单与准确装置。",
        "en": "Three pathways do not mean another LABA-, anticholinergic- or inhaled-corticosteroid-containing product can be self-added. Any addition, stopping, alternation or substitution needs a pharmacist or clinician to review the complete list and exact devices item by item."
      },
      {
        "zh": "“长期维持”“吸入”“支气管扩张”或共同的装置家族名都不能把本品变成急性症状的通用处理答案，也不能让一个装置的操作方法自动适用于另一装置。",
        "en": "‘Maintenance’, ‘inhalation’, ‘bronchodilation’ or a shared device-family name cannot turn this product into a general acute-symptom answer or make one device's operation automatically apply to another."
      },
      {
        "zh": "机制说明不能处理眼痛/视力改变、排尿困难、心悸、过敏、感染征象或任何严重呼吸症状。出现这些担忧时应使用当地医疗支持，不从机制文字自行调整。",
        "en": "A mechanism explanation cannot manage eye pain/vision change, urinary difficulty, palpitations, allergy, infection signs or any severe respiratory symptom. With these concerns, use local medical support rather than self-adjusting from mechanism text."
      }
    ],
    "source": {
      "id": "src_2a8f04a161167cfd",
      "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（Clinical Pharmacology；GSK；SPL v14）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "dated_public_record",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "scope": "mechanism_literacy_only_no_individual_dosing_or_substitution"
  },
  "pharmacovigilance": {
    "status": "official_routes_only_no_live_alert_inference",
    "reviewedAt": "2026-08-22",
    "identity": {
      "brand": "Trelegy Ellipta",
      "generic": "糠酸氟替卡松/乌美溴铵/维兰特罗",
      "dosageFormClass": "三成分干粉吸入器：100/62.5/25 或 200/62.5/25 mcg/次吸入（当前美国标签所列）"
    },
    "labelSource": {
      "id": "src_2a8f04a161167cfd",
      "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "dated_public_record",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "productRoutes": [
      {
        "source": {
          "id": "src_2a8f04a161167cfd",
          "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "dated_public_record",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        },
        "status": "product_level_public_record_verified",
        "authority": {
          "zh": "美国国家医学图书馆 DailyMed",
          "en": "U.S. National Library of Medicine DailyMed"
        },
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "recordType": {
          "zh": "公开药品标签",
          "en": "Public medicine label"
        },
        "reviewedAt": "2026-08-20",
        "scope": {
          "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。",
          "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk."
        }
      }
    ],
    "recordRoute": {
      "status": "product_level_public_record_verified",
      "authority": {
        "zh": "美国国家医学图书馆 DailyMed",
        "en": "U.S. National Library of Medicine DailyMed"
      },
      "market": {
        "zh": "美国",
        "en": "United States"
      },
      "recordType": {
        "zh": "公开药品标签",
        "en": "Public medicine label"
      },
      "reviewedAt": "2026-08-20",
      "scope": {
        "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。",
        "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk."
      }
    },
    "channels": [
      {
        "id": "china-nmpa-drug-evaluation-centre",
        "authority": "NMPA 药品评价中心",
        "market": {
          "zh": "中国大陆",
          "en": "Mainland China"
        },
        "title": {
          "zh": "药物警戒快讯与安全警示",
          "en": "Drug-vigilance bulletins and safety notices"
        },
        "purpose": {
          "zh": "国家药监局药品评价中心发布的药物警戒快讯、安全警示及药品不良反应监测相关原始入口；具体产品仍须按批准文号、剂型、规格、持有人和公告日期逐项核对。",
          "en": "Primary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item."
        },
        "source": {
          "id": "src_05ff2860226564d4",
          "label": "国家药监局药品评价中心：药物警戒与安全警示入口",
          "url": "https://www.cdr-adr.org.cn/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "CN",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "fda-drug-safety-communications",
        "authority": "FDA",
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "title": {
          "zh": "药物安全通讯",
          "en": "Drug Safety Communications"
        },
        "purpose": {
          "zh": "监管机构就重要新安全问题、标签变化或风险沟通发布的原始页面。",
          "en": "Primary FDA pages for important new safety issues, labelling changes and risk communications."
        },
        "source": {
          "id": "src_9177df9e1825aa72",
          "label": "FDA：Drug Safety Communications",
          "url": "https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "fda-medwatch",
        "authority": "FDA MedWatch",
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "title": {
          "zh": "安全信息与严重问题报告",
          "en": "Safety information and serious-problem reporting"
        },
        "purpose": {
          "zh": "美国 MedWatch 的安全信息和报告入口；报告不等同于已证实因果关系。",
          "en": "U.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality."
        },
        "source": {
          "id": "src_e4739cd55d27ab51",
          "label": "FDA：MedWatch 药品安全信息与不良事件报告计划",
          "url": "https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "ema-pharmacovigilance",
        "authority": "EMA",
        "market": {
          "zh": "欧盟/欧洲经济区",
          "en": "European Union / European Economic Area"
        },
        "title": {
          "zh": "药物警戒概览与 EudraVigilance",
          "en": "Pharmacovigilance overview and EudraVigilance"
        },
        "purpose": {
          "zh": "欧盟药物警戒、疑似不良反应报告和 PRAC 安全评估的官方入口。",
          "en": "Official EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment."
        },
        "source": {
          "id": "src_2ad42a3deae747d1",
          "label": "EMA：Pharmacovigilance overview",
          "url": "https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "EU",
          "accessStatus": "public_access_confirmed",
          "accessMode": "javascript_or_cookie_controls",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "mhra-drug-safety-update",
        "authority": "MHRA",
        "market": {
          "zh": "英国",
          "en": "United Kingdom"
        },
        "title": {
          "zh": "Drug Safety Update",
          "en": "Drug Safety Update"
        },
        "purpose": {
          "zh": "英国 MHRA 面向专业人士和公众的药品安全更新原始发布页。",
          "en": "Primary UK MHRA medicine-safety updates for professionals and the public."
        },
        "source": {
          "id": "src_23fdbe67abeafc63",
          "label": "MHRA：Drug Safety Update",
          "url": "https://www.gov.uk/drug-safety-update",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "UK",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "pmda-drug-safety",
        "authority": "PMDA",
        "market": {
          "zh": "日本",
          "en": "Japan"
        },
        "title": {
          "zh": "药品安全信息",
          "en": "Medicine safety information"
        },
        "purpose": {
          "zh": "日本 PMDA 药品安全信息的英文官方入口；具体产品仍应以日文产品页和现行文件复核。",
          "en": "PMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents."
        },
        "source": {
          "id": "src_06d6be2880f12024",
          "label": "PMDA：Safety Information Regarding Drugs",
          "url": "https://www.pmda.go.jp/english/safety/info-services/drugs/0001.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "JP",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "mfds-drug-safety-letters",
        "authority": "MFDS",
        "market": {
          "zh": "韩国",
          "en": "Republic of Korea"
        },
        "title": {
          "zh": "药品安全性书信",
          "en": "Medicine safety letters"
        },
        "purpose": {
          "zh": "韩国 MFDS 发布的药品安全性书信原始索引。原文为韩文，须按涉及产品、剂型、市场和日期逐项阅读；它不自动适用于其他市场，也不构成对个人情况的结论。",
          "en": "MFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case."
        },
        "source": {
          "id": "src_2d7f5018cd05eff4",
          "label": "MFDS：药品安全性书信（韩文原始资料）",
          "url": "https://www.mfds.go.kr/brd/m_545/list.do",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "KR",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "hsa-adverse-events",
        "authority": "HSA",
        "market": {
          "zh": "新加坡",
          "en": "Singapore"
        },
        "title": {
          "zh": "不良反应报告与药物安全信息",
          "en": "Adverse-event reporting and medicine-safety information"
        },
        "purpose": {
          "zh": "新加坡 HSA 面向公众的疑似不良反应报告、药物安全信息与本地监管入口；一份报告不等同于个体因果关系，具体产品仍须按新加坡注册状态、剂型、规格、日期和现行产品资料逐项核对。",
          "en": "HSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information."
        },
        "source": {
          "id": "src_9240397d5a8574c1",
          "label": "HSA：Report adverse events",
          "url": "https://www.hsa.gov.sg/adverse-events/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "SG",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "health-canada-medeffect-advisories",
        "authority": "Health Canada",
        "market": {
          "zh": "加拿大",
          "en": "Canada"
        },
        "title": {
          "zh": "MedEffect 加拿大：建议、警告与召回",
          "en": "MedEffect Canada: advisories, warnings and recalls"
        },
        "purpose": {
          "zh": "加拿大政府 Health Canada 的 MedEffect 公开入口，汇集药品及健康产品的建议、警告、召回、报告与安全信息；具体产品仍须按市场、剂型、规格、公告日期和批号逐项核对。",
          "en": "Health Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item."
        },
        "source": {
          "id": "src_212ec921fa6634ad",
          "label": "Health Canada：MedEffect Canada 建议、警告与召回",
          "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/advisories-warnings-recalls.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "CA",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "tga-safety-alerts",
        "authority": "TGA",
        "market": {
          "zh": "澳大利亚",
          "en": "Australia"
        },
        "title": {
          "zh": "药品安全警示",
          "en": "Medicine safety alerts"
        },
        "purpose": {
          "zh": "澳大利亚 TGA 的药品安全警示、建议和监测信息原始发布页。",
          "en": "Primary Australian TGA safety alerts, advisories and monitoring information for therapeutic products."
        },
        "source": {
          "id": "src_ffe6142814f88fac",
          "label": "TGA：Safety alerts",
          "url": "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "AU",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "swissmedic-pharmacovigilance",
        "authority": "Swissmedic",
        "market": {
          "zh": "瑞士",
          "en": "Switzerland"
        },
        "title": {
          "zh": "药物警戒与不良反应报告",
          "en": "Pharmacovigilance and suspected adverse-reaction reporting"
        },
        "purpose": {
          "zh": "瑞士 Swissmedic 的药物警戒、信号评估和疑似不良反应官方入口；报告或信号本身不等同于对个体因果关系的确认。",
          "en": "Official Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality."
        },
        "source": {
          "id": "src_c854f813ce2671df",
          "label": "Swissmedic：Pharmacovigilance",
          "url": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/pharmacovigilance.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "CH",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "medsafe-safety-communications",
        "authority": "Medsafe",
        "market": {
          "zh": "新西兰",
          "en": "New Zealand"
        },
        "title": {
          "zh": "药品安全通讯",
          "en": "Medicine safety communications"
        },
        "purpose": {
          "zh": "新西兰 Medsafe 面向公众和专业人士的药品安全通讯与归档入口；旧公告可能已被现行产品资料更新。",
          "en": "New Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information."
        },
        "source": {
          "id": "src_3510c1a523ec9769",
          "label": "Medsafe：Safety Communications",
          "url": "https://www.medsafe.govt.nz/safety/SafetyCommunications.asp",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "NZ",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "sahpra-safety-information",
        "authority": "SAHPRA",
        "market": {
          "zh": "南非",
          "en": "South Africa"
        },
        "title": {
          "zh": "药物安全信息、警示与药物警戒",
          "en": "Medicine safety information, alerts and pharmacovigilance"
        },
        "purpose": {
          "zh": "南非 SAHPRA 面向公众和专业人士的药物安全信息、警示与药物警戒入口；官方警示不等同于产品在所有情形下不安全，具体产品仍须按南非注册状态、剂型、规格、公告日期与现行资料逐项核对。",
          "en": "SAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information."
        },
        "source": {
          "id": "src_25b0aaefee742163",
          "label": "SAHPRA：Safety Information Updates / Pharmacovigilance",
          "url": "https://www.sahpra.org.za/safety-information-and-updates/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "ZA",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "who-medicine-safety-alerts",
        "authority": "WHO",
        "market": {
          "zh": "全球",
          "en": "Global"
        },
        "title": {
          "zh": "药品与疫苗安全警示档案",
          "en": "Medicine and vaccine safety-alert archive"
        },
        "purpose": {
          "zh": "WHO 的跨市场安全警示档案；每条历史警示必须按公告日期、涉及产品和市场单独阅读。",
          "en": "WHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market."
        },
        "source": {
          "id": "src_9a7dc56ec34c7e1a",
          "label": "WHO：Safety alerts for medicines and vaccines",
          "url": "https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/safety-alerts",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "GLOBAL",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "anvisa-pharmacovigilance",
        "authority": "Anvisa",
        "market": {
          "zh": "巴西",
          "en": "Brazil"
        },
        "title": {
          "zh": "药物警戒、警示与 VigiMed",
          "en": "Pharmacovigilance, alerts and VigiMed"
        },
        "purpose": {
          "zh": "巴西 Anvisa 的药物警戒原始入口，涵盖警示、药物警戒公告、风险沟通和 VigiMed 报告路径；具体产品仍须按巴西批准状态、剂型、规格和公告日期逐项核对。",
          "en": "Anvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item."
        },
        "source": {
          "id": "src_5de362c12580111d",
          "label": "Anvisa：Farmacovigilância（药物警戒、警示与 VigiMed）",
          "url": "https://www.gov.br/anvisa/pt-br/assuntos/fiscalizacao-e-monitoramento/farmacovigilancia",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "BR",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      }
    ],
    "notices": [],
    "boundary": {
      "zh": "本卡将逐药产品级来源与 15 个市场级官方警戒入口放在同一处核验；它不表示已完成该药在所有国家或地区的实时警示检索，也不表示该药存在新的安全警示、召回或风险结论。请先以品牌名、通用名、剂型、规格、所在市场和公告日期逐项匹配；不要仅因看到标题自行停药、换药、加量或减量。",
      "en": "This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline."
    },
    "scope": "official_routes_only_no_live_alert_inference"
  },
  "archive": {
    "summary": "DailyMed 当前 TRELEGY ELLIPTA 标签将其列为含糠酸氟替卡松、乌美溴铵和维兰特罗的三成分干粉吸入器。本页帮助核对完整品牌、全部三种成分、完整三数字、吸入装置、包装、标签版本和目标市场；不把任何数字变成个人吸入次数、使用步骤、加减量、补用、转换或联合方案。",
    "history": "当前美国标签列示 Initial U.S. Approval: 2017，SPL v14 于 2025-11-19 公开。其三种成分与 VENTOLIN HFA、ANORO ELLIPTA、INCRUSE ELLIPTA、BREO ELLIPTA 等产品的成分数量或用途线索不同；名称相近或均为吸入产品不能证明可自行替代、加用或把本品作为急性症状缓解药。",
    "sourceDocuments": [
      {
        "id": "src_2a8f04a161167cfd",
        "label": "DailyMed（NLM）：TRELEGY ELLIPTA 糠酸氟替卡松/乌美溴铵/维兰特罗当前美国公开标签（GSK；SPL v14）",
        "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "product_label",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      }
    ],
    "applicationNumber": "NDA 209482",
    "approvalTimeline": [
      {
        "date": "2017-09-18",
        "title": {
          "zh": "NDA 209482 原始申请批准",
          "en": "NDA 209482 original application approval"
        },
        "detail": {
          "zh": "FDA Drugs@FDA 公开记录将 TRELEGY ELLIPTA 的原始申请（ORIG 1）标为 2017-09-18 获批；该美国监管节点不建立其他市场的批准、供应或个人适用性。",
          "en": "The FDA Drugs@FDA public record lists TRELEGY ELLIPTA original application (ORIG 1) as approved on 18 Sep 2017. This U.S. regulatory node does not establish approval, supply or individual suitability in another market."
        },
        "source": {
          "id": "src_e7b5a9ecc4741628",
          "label": "FDA: TRELEGY ELLIPTA NDA 209482 original approval letter (2017-09-18)",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209482Orig1s000ltr.pdf",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "historical_public_record",
          "documentKind": "approval_record",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "direct_document",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        }
      },
      {
        "date": "2017",
        "title": {
          "zh": "当前标签所列美国初始批准年份",
          "en": "Initial U.S. approval year listed in the current label"
        },
        "detail": {
          "zh": "当前 TRELEGY ELLIPTA 标签列示 Initial U.S. Approval: 2017；该年份不自动说明其他市场的产品状态。",
          "en": "The current TRELEGY ELLIPTA label lists Initial U.S. Approval: 2017; it does not establish product status in another market."
        },
        "source": {
          "id": "src_2a8f04a161167cfd",
          "label": "DailyMed: current TRELEGY ELLIPTA public label, SPL v14",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "dated_public_record",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        }
      },
      {
        "date": "2025-11-19",
        "title": {
          "zh": "DailyMed 公开当前 SPL v14",
          "en": "Current SPL v14 published on DailyMed"
        },
        "detail": {
          "zh": "DailyMed 将当前 v14 的 Published Date 列为 2025-11-19；该日期不代表个人使用、可售或供应状态。",
          "en": "DailyMed lists 19 Nov 2025 as the current v14 Published Date; it does not represent individual use, availability or supply status."
        },
        "source": {
          "id": "src_2a8f04a161167cfd",
          "label": "DailyMed: current TRELEGY ELLIPTA public label, SPL v14",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e&version=14",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "dated_public_record",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        }
      }
    ],
    "marketStatus": [
      {
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "status": {
          "zh": "已链接当前三成分标签与一个精确纸盒面板",
          "en": "Current three-ingredient label and one exact carton panel linked"
        },
        "detail": {
          "zh": "展示图只对应 100/62.5/25 mcg、NDC 0173-0887-10、30 次吸入（60 个泡罩）；不据此建立实际在售、库存、个人操作或其他规格状态。",
          "en": "The image corresponds only to 100/62.5/25 mcg, NDC 0173-0887-10 and 30 inhalations (60 blisters); it does not establish actual marketing, stock, individual device operation or another-strength status."
        }
      },
      {
        "market": {
          "zh": "中国大陆、欧盟、日本及其他市场",
          "en": "Mainland China, EU, Japan and other markets"
        },
        "status": {
          "zh": "待逐项建立市场记录",
          "en": "Market record not established"
        },
        "detail": {
          "zh": "不从美国标签推定当地商品名、批准、装置、供应、原研关系或可替代性。",
          "en": "No local trade name, approval, device, supply, originator relationship or interchangeability is inferred from the U.S. label."
        }
      }
    ],
    "frequentlyAskedQuestions": [
      {
        "question": {
          "zh": "100/62.5/25 mcg 是不是可以只看其中一个数字？",
          "en": "Can 100/62.5/25 mcg be read as just one of its three numbers?"
        },
        "answer": {
          "zh": "不能。它是这一准确三成分吸入产品每次吸入的完整身份标示。页面不把它变成个人吸入次数、装置操作、调整或与其他吸入产品的换算。",
          "en": "No. It is the complete per-inhalation identity marking for this exact three-ingredient inhaler. The page does not turn it into individual inhalation use, device operation, adjustment or conversion to another inhaler."
        }
      },
      {
        "question": {
          "zh": "TRELEGY ELLIPTA 能否和其他 ELLIPTA 或急救吸入药自行互换？",
          "en": "Can TRELEGY ELLIPTA be self-switched with another ELLIPTA or rescue inhaler?"
        },
        "answer": {
          "zh": "不能。相近装置名、共同成分或都用于呼吸系统并不建立可自行互换关系。标签也明确本品不用于缓解急性支气管痉挛；请带实际装置和完整药单咨询药师或开方团队。",
          "en": "No. Similar device names, shared ingredients or respiratory use do not establish self-interchangeability. The label also states it is not for relief of acute bronchospasm; take the actual devices and complete medicine list to a pharmacist or prescribing team."
        }
      }
    ],
    "relatedMedicineChecks": [],
    "relatedArticleSlugs": [
      "medicine-label-for-everyday-questions",
      "dosage-forms-are-part-of-medicine-identity",
      "how-to-read-a-drug-label"
    ]
  },
  "canonicalUrls": {
    "zh": "https://origindrug.com/drugs/trelegy-ellipta/",
    "en": "https://origindrug.com/en/drugs/trelegy-ellipta/"
  },
  "limitations": [
    "No originator, generic, interchangeability, availability, price, holder, strength or sale-eligibility conclusion is inferred beyond the linked source documents.",
    "Target-market current labels and official records must be checked separately."
  ]
}